

OSOBNJE INFORMACIJE

Nikica Mirošević Skvrce

ZVANJE Farmaceut

TITULA Dr.sc.

RADNO ISKUSTVO

01.2020 -

Glavni savjetnik

HALMED

01.2005 -

Glavni koordinator za nova sigurnosna pitanja u Odsjeku za farmakovigilanciju i racionalnu farmakoterapiju

Agencija za lijekove i medicinske proizvode, Ksaverska cesta 4, www.halmed.hr

www.halmed.hr

OBRAZOVANJE I  
OSPOBLJAVANJE

09.2012 - 09.2014

Magistar znanosti

European Programme in Pharmacovigilance and Pharmacoepidemiology

09.2007 - 06.2014

Doktor znanosti

Medicinski fakultet

09.1998 - 02.2004

Magistar farmacije

Farmaceutsko-biokemijski fakultet

OSOBNJE VJEŠTINE

Ostali jezici	RAZUMIJEVANJE		GOVOR		PISANJE
	Slušanje	Čitanje	Govorna interakcija	Govorna produkcija	
Engleski	C1/2: Iskusni korisnik	C1/2: Iskusni korisnik	C1/2: Iskusni korisnik	B1/2: Samostalni korisnik	B1/2: Samostalni korisnik
Engleski	C1/2: Iskusni korisnik	C1/2: Iskusni korisnik	C1/2: Iskusni korisnik	B1/2: Samostalni korisnik	B1/2: Samostalni korisnik

Vozačka dozvola B

DODATNE INFORMACIJE

## Izdanja

1. Božina N, Vrkić Kirhmajer M, Šimičević L, Ganoci L, Mirošević Skvrce N, Klarica Domjanović I, Merčep I. Use of pharmacogenomics in elderly patients treated for cardiovascular diseases. *Croat Med J.* 2020 Apr 30;61(2):147-158. doi: 10.3325/cmj.2020.61.147
2. Skvrce NM, Krivokapić S, Božina N. Implementation of pharmacogenomics in product information. *Pharmacogenomics.* 2020 May;21(7):443-448. doi: 10.2217/pgs-2019-0166. Epub 2020 Apr 27. PMID: 32336208
3. Mirosevic Skvrce N, Galic I, Pacadi C, Kandzija N, Mucalo I. Adverse drug reactions that arise from the use of medicinal products outside the terms of the marketing authorisation. *Res Social Adm Pharm.* 2020 Jul;16(7):928-934. doi: 10.1016/j.sapharm.2019.10.003. Epub 2019 Oct 7. PMID: 31630960
4. Ganoci L, Božina T, Mirošević Skvrce N, Lovrić M, Mas P, Božina N. Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population. *Drug Metab Pers Ther.* 2017 Mar 1;32(1):11-21. doi: 10.1515/dmpt-2016-0024. PMID: 28272018
5. Božina N, Mirosevic Skvrce N, Ganoci L, Mas P, Klarica Domjanovic I, Simic I. Integrating Pharmacovigilance and Pharmacogenomics: Croatian Experience. *Clin Ther.* 2016 Oct 6;38(10S):e23. doi: 10.1016/j.clinthera.2016.07.142.
6. Stanić BeniĆ M, Mirošević Skvrce N, Božina N. The Role of Pharmacogenetic Testing in the Evaluation of Drug-Induced Liver Injury. *Clin Ther.* 2016 Oct 6;38(10S):e24-e25. doi: 10.1016/j.clinthera.2016.07.145.
7. Mirošević Skvrce N, Macolić Šarinić V, Šimić I, Ganoci L, Muačević Katanec D, Božina N. ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study. *Pharmacogenomics.* 2015 Jul;16(8):803-15. doi: 10.2217/pgs.15.47. Epub 2015 Jun 18. PMID: 26086347
8. Mirošević Skvrce N, Božina N, Zibar L, Barišić I, Pejnović L, Macolić Šarinić V. CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study. *Pharmacogenomics.* 2013 Sep;14(12):1419-31. doi: 10.2217/pgs.13.135. PMID: 24024895
9. Mirosevic Skvrce N, Macolic Sarinic V, Mucalo I, Krnic D, Božina N, Tomic S. Adverse drug reactions caused by drug-drug interactions reported to Croatian Agency for Medicinal Products and Medical Devices: a retrospective observational study. *Croat Med J.* 2011 Oct 15;52(5):604-14. doi: 10.3325/cmj.2011.52.604. PMID: 21990078
10. Skvrce NM, Božina N, Sarinić VM, Tomić S. Adverse drug reactions of hydroxymethylglutaryl-CoA reductase inhibitors reported to agency for medicinal products and medical devices. *Lijec Vjesn.* 2010 Sep-Oct;132(9-10):277-82. PMID: 21261024 Croatian.
11. Skvrce NM, Arapović S, Krić D, Sarinić VM, Zezelić S, Bagatin K, Leventić J, Tomić S. Adverse drug reactions of psychopharmacs. *Psychiatr Danub.* 2010 Sep;22(3):441-5. PMID: 20856189

## Projekti

ADVANCE  
SCOPE

## Priznanja i nagrade

Na 2. Zajedničkom kongresu EFLM i UEMS: prva nagradu za najbolji poster pod naslovom „ABCG2 gene variant and fluvastatin adverse drug reactions in renal transplant recipients“.

Članstva

ISOP  
ENCePP